Quick Answer
Pelthos Therapeutics Inc. reported Total Revenue of $16.80 million for fiscal year 2025.
Pelthos Therapeutics Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | $16.80M | $0.00 | — | — | — |
| Revenue (ASC 606) | $16.80M | $0.00 | — | — | — |
| Net Income | -$43.32M -444.6% |
-$7.96M -7.8% |
-$7.38M -200.2% |
-$2.46M | — |
| Diluted EPS | -$23.04 -61.5% |
-$14.27 -146.9% |
-$5.78 | — | — |
| Total Assets | $130.40M +9425.0% |
$1.37M +1320.3% |
$96.4K +75.0% |
$55.1K | — |
| Cash and Equivalents | $17.97M +3403.5% |
$513.0K | — | — | — |
| Stockholders Equity | $38.88M +1532.6% |
-$2.71M +57.9% |
-$6.45M -73.9% |
-$3.71M -0.7% |
-$3.68M |
| R&D Expense | $1.23M +4.2% |
$1.18M -54.3% |
$2.58M +558.5% |
$391.7K | — |
| Operating Income | -$32.43M -328.3% |
-$7.57M -10.3% |
-$6.86M -196.0% |
-$2.32M | — |
| Shares Outstanding | 3.23M +429.9% |
610,389 -84.4% |
3.91M +229.0% |
1.19M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $7.41M | — | — |
| Revenue (ASC 606) | September 30, 2025 | $294.0K | — | — |
| Net Income | September 30, 2025 | -$16.24M | -858.0% | -370.8% |
| Diluted EPS | September 30, 2025 | -$5.30 | -80.9% | +1.5% |
| Total Assets | September 30, 2025 | $126.43M | +5808.4% | +15265.3% |
| Stockholders Equity | September 30, 2025 | $58.25M | +4179.3% | +997.0% |
| R&D Expense | September 30, 2025 | $145.0K | -65.1% | -71.8% |
| Operating Income | September 30, 2025 | -$15.36M | -649.7% | -375.5% |
| Shares Outstanding | September 30, 2025 | 3.09M | -46.9% | +359.0% |
- Pelthos Therapeutics Inc. reported Total Revenue of $16.80 million for fiscal year 2025.
- Pelthos Therapeutics Inc. reported Revenue (ASC 606) of $16.80 million for fiscal year 2025.
- Pelthos Therapeutics Inc. reported Net Income of -$43.32 million for fiscal year 2025.
- Pelthos Therapeutics Inc. showed a decrease of -444.6% in Net Income compared to the prior fiscal year.
- Pelthos Therapeutics Inc. reported Diluted EPS of $23.04 per share (loss) for fiscal year 2025.
- Pelthos Therapeutics Inc. showed a decrease of -61.5% in Diluted EPS compared to the prior fiscal year.
- Pelthos Therapeutics Inc. reported Total Assets of $130.40 million for fiscal year 2025.
- Pelthos Therapeutics Inc. showed an increase of +9425.0% in Total Assets compared to the prior fiscal year.
- Pelthos Therapeutics Inc. reported Cash and Equivalents of $17.97 million for fiscal year 2025.
- Pelthos Therapeutics Inc. showed an increase of +3403.5% in Cash and Equivalents compared to the prior fiscal year.
- Pelthos Therapeutics Inc. reported Stockholders Equity of $38.88 million for fiscal year 2025.
- Pelthos Therapeutics Inc. showed an increase of +1532.6% in Stockholders Equity compared to the prior fiscal year.
- Pelthos Therapeutics Inc. reported R&D Expense of $1.23 million for fiscal year 2025.
- Pelthos Therapeutics Inc. showed an increase of +4.2% in R&D Expense compared to the prior fiscal year.
- Pelthos Therapeutics Inc. reported Operating Income of -$32.43 million for fiscal year 2025.
- Pelthos Therapeutics Inc. showed a decrease of -328.3% in Operating Income compared to the prior fiscal year.
- Pelthos Therapeutics Inc. reported Shares Outstanding of 3.23 million shares for fiscal year 2025.
- Pelthos Therapeutics Inc. showed an increase of +429.9% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: